Latest Articles

Publication Date
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial - Nature.com

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial Nature.com

Published: March 5, 2025, 11:04 a.m.
Patterns of associations with epidemiologic factors by high grade serous ovarian cancer gene expression subtypes.

Ovarian high-grade serous carcinomas (HGSC) comprise four distinct molecular subtypes based on mRNA expression patterns, with differential survival. Understanding risk factor associations is important to elucidate the etiology of HGSC. …

Published: Feb. 26, 2025, midnight
Long-Term Survival of Endometriosis-Related Ovarian Clear Cell Carcinoma with Endometriosis Surgical History.

Background/Objectives: The prognosis of endometriosis-related ovarian clear cell carcinoma (OCCC) versus non-endometriosis-associated OCCC remains unclear. We examined the impact of endometriosis on OCCC diagnosis and progression and assessed whether prior …

Published: Feb. 26, 2025, midnight
Risk factors, survival analysis, and nomograms for high-grade endometrial stromal sarcoma patients with distant metastasis: A population-based study (2010-2019) - Frontiers

Risk factors, survival analysis, and nomograms for high-grade endometrial stromal sarcoma patients with distant metastasis: A population-based study (2010-2019) Frontiers

Published: Feb. 24, 2025, 1:38 p.m.
Survival Outcomes in Advanced Endometrial Cancer with Lenvatinib plus Pembrolizumab - Physician's Weekly

Survival Outcomes in Advanced Endometrial Cancer with Lenvatinib plus Pembrolizumab Physician's Weekly

Published: Feb. 4, 2025, 11:09 a.m.
Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer - OncLive

Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer OncLive

Published: Jan. 30, 2025, 10:54 p.m.
Does Chemoradiotherapy Boost Survival in Endometrial Cancer? - Medscape

Does Chemoradiotherapy Boost Survival in Endometrial Cancer? Medscape

Published: Jan. 21, 2025, 9:45 a.m.
Neutrophils initiate pro-inflammatory immune responses in early endometriosis lesion development.

Endometriosis is a chronic gynecological disease that affects 1 in 10 reproductive-aged women. Most studies investigate established disease; however, the initiation and early events in endometriotic lesion development remain poorly …

Published: Jan. 21, 2025, midnight
Potential Modulatory Role of Phoenixin-14 in Epithelial-Mesenchymal Transition of Endometriotic 12Z Cells.

Background/Objectives: Endometriosis is a painful chronic condition in which the endometrium grows outside the uterus. The epithelial-mesenchymal transition (EMT) is critical to endometriosis progression, where cells lose epithelial traits and …

Published: Jan. 10, 2025, midnight
Validation of Tumor Budding as a Prognostic Factor in Ovarian Clear Cell Carcinoma Using an Independent Cohort.

Ovarian clear cell carcinoma (OCCC) is an endometriosis-related neoplasm, in which traditional histologic grading does not show prognostic significance. Tumor budding was associated with poorer outcomes in OCCC in previous …

Published: Jan. 10, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!